Add-on to current guidelines for monitoring of SBS patients treated with teduglutide

By inducing growth of the intestinal epithelium, the drug teduglutide, used for the treatment of short bowel syndrome-associated intestinal failure, could feasibly promote growth of pre-existing colonic neoplasms and incite the development of new ones. A baseline screen for colonic lesions and a 1-year follow-up have therefore been recommended, although an ongoing global prospective registry has, to date, shown no promotion of colonic neoplasms. Most recently, there have been reports of patients developing upper intestinal polyps while on the drug, including ones with malignant potential. To ensure patient safety, the Committee overseeing the global registry therefore recommends that monitoring strategies be updated to include screening for small intestinal lesions as well.

Authors

Institutions

Publication Details

Journal
npj gut and liver.
Published
2026-01-06
DOI
https://doi.org/10.1038/s44355-025-00047-7
Primary Topic
Clinical Nutrition and Gastroenterology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Add-on to current guidelines for monitoring of SBS patients treated with teduglutide

Gabriel Eduardo Gondolesi, UF Pape, Joel B. Mason, Francisca Joly et al.
npj gut and liver.
Clinical Nutrition and Gastroenterology
article

Add-on to current guidelines for monitoring of SBS patients treated with teduglutide

Gabriel Eduardo Gondolesi, UF Pape, Joel B. Mason, Francisca Joly, J. Allard, Loris Pironi, Lauren K. Schwartz, Palle Bekker Jeppesen, Martina Kohl-Sobania
article en

Abstract

By inducing growth of the intestinal epithelium, the drug teduglutide, used for the treatment of short bowel syndrome-associated intestinal failure, could feasibly promote growth of pre-existing colonic neoplasms and incite the development of new ones. A baseline screen for colonic lesions and a 1-year follow-up have therefore been recommended, although an ongoing global prospective registry has, to date, shown no promotion of colonic neoplasms. Most recently, there have been reports of patients developing upper intestinal polyps while on the drug, including ones with malignant potential. To ensure patient safety, the Committee overseeing the global registry therefore recommends that monitoring strategies be updated to include screening for small intestinal lesions as well.

npj gut and liver.Vol. 3(1)
Tufts University (US), Tufts Medical Center (US), University of Toronto (CA), Hôpital Beaujon (FR), Toronto General Hospital (CA), Rigshospitalet (DK), NYU Langone Health (US), MSH Medical School Hamburg – University of Applied Sciences and Medical University (DE), University Hospital Schleswig-Holstein (DE), Asklepios Klinik St. Georg (DE), Fundacion Favaloro Hospital Universitario (AR), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Charité - Universitätsmedizin Berlin (DE), University of Lübeck (DE), University of Bologna (IT)
Good health and well-being
Openalex Percentile: Top 97%
Clinical Nutrition and Gastroenterology
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.